Literature DB >> 23558600

Lixisenatide: first global approval.

Shelley Elkinson1, Gillian M Keating.   

Abstract

The selective once-daily prandial glucagon-like peptide-1 (GLP-1) receptor agonist lixisenatide (Lyxumia(®)) is under development with Sanofi for the treatment of type 2 diabetes mellitus. Lixisenatide belongs to a class of GLP-1 compounds designed to mimic the endogenous hormone GLP-1. Native GLP-1 stimulates insulin secretion in a glucose-dependent manner, as well as suppressing glucagon production and slowing gastric emptying. A once-daily subcutaneous formulation of lixisenatide has been approved in the EU, Iceland, Liechtenstein, Norway and Mexico for the treatment of type 2 diabetes, and is under regulatory review in the USA, Switzerland, Brazil, Canada, Ukraine, South Africa, Japan and Australia. This article summarizes the milestones in the development of lixisenatide, leading to this first approval for use in adults with type 2 diabetes.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23558600     DOI： 10.1007/s40265-013-0033-3

Source DB:  PubMed          Journal:  Drugs        ISSN： 0012-6667            Impact factor:   9.546


  9 in total

Review 1.  Pharmacological profile of lixisenatide: A new GLP-1 receptor agonist for the treatment of type 2 diabetes.

Authors:  Ulrich Werner; Guido Haschke; Andreas W Herling; Werner Kramer
Journal:  Regul Pept       Date:  2010-06-02

Review 2.  Glucagon-like peptide-1 analogues for Type 2 diabetes mellitus: current and emerging agents.

Authors:  Baptist Gallwitz
Journal:  Drugs       Date:  2011-09-10       Impact factor: 9.546

3.  Glucagon-like peptide 1 receptor agonist ZP10A increases insulin mRNA expression and prevents diabetic progression in db/db mice.

Authors:  Christian Thorkildsen; Søren Neve; Bjarne Due Larsen; Eddi Meier; Jørgen Søberg Petersen
Journal:  J Pharmacol Exp Ther       Date:  2003-09-15       Impact factor: 4.030

Review 4.  Mechanisms and clinical efficacy of lixisenatide for the management of type 2 diabetes.

Authors:  Michael Horowitz; Christopher K Rayner; Karen L Jones
Journal:  Adv Ther       Date:  2013-02-13       Impact factor: 3.845

Review 5.  Lixisenatide, a novel GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus.

Authors:  Mikkel Christensen; Filip K Knop; Jens J Holst; Tina Vilsboll
Journal:  IDrugs       Date:  2009-08

6.  Dose-dependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled trial.

Authors:  R E Ratner; J Rosenstock; G Boka
Journal:  Diabet Med       Date:  2010-09       Impact factor: 4.359

7.  Efficacy and safety of the once-daily GLP-1 receptor agonist lixisenatide in monotherapy: a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes (GetGoal-Mono).

Authors:  Vivian A Fonseca; Ricardo Alvarado-Ruiz; Denis Raccah; Gabor Boka; Patrick Miossec; John E Gerich
Journal:  Diabetes Care       Date:  2012-03-19       Impact factor: 19.112

8.  Randomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal-L-Asia).

Authors:  Y Seino; K W Min; E Niemoeller; A Takami
Journal:  Diabetes Obes Metab       Date:  2012-05-30       Impact factor: 6.577

9.  Pharmacodynamic characteristics of lixisenatide once daily versus liraglutide once daily in patients with type 2 diabetes insufficiently controlled on metformin.

Authors:  C Kapitza; T Forst; H-V Coester; F Poitiers; P Ruus; A Hincelin-Méry
Journal:  Diabetes Obes Metab       Date:  2013-02-25       Impact factor: 6.577
  9 in total
  7 in total

1.  Lixisenatide accelerates restoration of normoglycemia and improves human beta-cell function and survival in diabetic immunodeficient NOD-scid IL-2rg(null) RIP-DTR mice engrafted with human islets.

Authors:  Chaoxing Yang; Matthias Loehn; Agata Jurczyk; Natalia Przewozniak; Linda Leehy; Pedro L Herrera; Leonard D Shultz; Dale L Greiner; David M Harlan; Rita Bortell
Journal:  Diabetes Metab Syndr Obes       Date:  2015-08-20       Impact factor: 3.168

Review 2.  Optimal therapy of type 2 diabetes: a controversial challenge.

Authors:  Angela Dardano; Giuseppe Penno; Stefano Del Prato; Roberto Miccoli
Journal:  Aging (Albany NY)       Date:  2014-03       Impact factor: 5.682

Review 3.  High drug-loading nanomedicines: progress, current status, and prospects.

Authors:  Shihong Shen; Youshen Wu; Yongchun Liu; Daocheng Wu
Journal:  Int J Nanomedicine       Date:  2017-05-31

Review 4.  Insulin Signaling Impairment in the Brain as a Risk Factor in Alzheimer's Disease.

Authors:  Christian Hölscher
Journal:  Front Aging Neurosci       Date:  2019-04-24       Impact factor: 5.750

Review 5.  Islet cell plasticity and regeneration.

Authors:  Adriana Migliorini; Erik Bader; Heiko Lickert
Journal:  Mol Metab       Date:  2014-01-22       Impact factor: 7.422

Review 6.  Lixisenatide as add-on therapy to basal insulin.

Authors:  Dominique Xavier Brown; Emma Louise Butler; Marc Evans
Journal:  Drug Des Devel Ther       Date:  2013-12-13       Impact factor: 4.162

7.  Lixisenatide: A New Member of the Glucagon-Like Peptide 1 Receptor Agonist Class of Incretin Therapies.

Authors:  Charles F Shaefer
Journal:  Clin Diabetes       Date:  2016-04
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.